Seeking Alpha

Rosetta sets strategic alliance

  • Pico caps Rosetta Genomics (ROSG) and Marina Biotech (MRNA) establish a strategic collaboration to identify and develop microRNA-based products targeting neuromuscular diseases and dystrophies.
  • Initial focus will be Becker and Duchenne muscular dystrophies and myotonic dystrophy.
  • Rosetta will identify microRNAs associated with the diseases and, if correlative, will develop the diagnostic products. Marina will develop the therapeutics.
Comments (1)
  • Jerome Verony
    , contributor
    Comments (17) | Send Message
     
    financial terms of this new 'alliance' unfortunately not disclosed. Why?
    2 Apr, 02:44 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|